Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: Results of a multicenter phase I/II study

Acta Oncologica

Volumn 53, Issue 3, 2014, Pages 392-398

  Stein, Alexander ^a   Arnold, Dirk ^b   Thuss Patience, Peter C ^c   Moehler, Markus ^d   Grothe, Wilfried ^e   Seufferlein, Thomas ^f   Reinacher Schick, Anke ^g   Geissler, Michael ^h   Hofheinz, Ralf Dieter ⁱ   Schmoll, Hans Joachim ^j  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b TUMOR BIOLOGY CENTER   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^e Asklepios Klinik Harburg   (Germany)

^f UNIVERSITY OF ULM   (Germany)

^g ST JOSEF HOSPITAL   (Germany)

^h KLINIKUM ESSLINGEN   (Germany)

ⁱ UNIVERSITY OF HEIDELBERG   (Germany)

^j MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; DOCETAXEL; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; TRASTUZUMAB; ALKALINE PHOSPHATASE; BILIRUBIN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CREATININE CLEARANCE; DIARRHEA; DISEASE CONTROL; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TOXICITY; ELECTROCORTICOGRAPHY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROESOPHAGEAL CANCER; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; INFECTION; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; METASTATIC GASTRIC CANCER; MIDDLE AGED; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; SENSORY NEUROPATHY; SEPSIS; STOMACH CANCER; THROMBOCYTE COUNT; VERY ELDERLY; ALKALINE PHOSPHATASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER STAGING; CLINICAL ARTICLE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; ESOPHAGUS CANCER; ESOPHAGUS METASTASIS; LIVER FUNCTION; MILD RENAL IMPAIRMENT; MULTIPLE CYCLE TREATMENT; PERIPHERAL NEUROPATHY; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; STOMACH NEOPLASMS; TAXOIDS; TREATMENT OUTCOME;

EID: 84894183457     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2013.833346     Document Type: Article

References (25)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90.
2. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569-78.
3. Malvezzi M, Arfe A, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2011. Ann Oncol 2011;22:947-56.
4. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41.
5. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-91.
6. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163-8.
7. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol 2006; 24:4991-7.
8. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46.
9. Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluor-ouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002; 20:1996-2004.
10. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97.
11. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: The V-325 Study Group. J Clin Oncol 2007;25:3210-6.
12. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: A randomised phase III noninferiority trial. Ann Oncol 2009;20:666-73.
13. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: A study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008;26:1435-42.
14. Okines AF, Norman AR, McCloud P, Kang YK, Cunningham D. Meta-analysis of the REAL-2 and ML17032 trials: Evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 2009;20:1529-34.
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research andTreatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
16. Goel G, Jauhri M, Negi A, Aggarwal S. Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma. Hematol Oncol Stem Cell Ther 2010;3:55-9.
17. Al-Batran SE, Hartmann JT, Hofheinz R, Homann N, Rethwisch V, Probst S, et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: A phase II trial of the Arbeitsge-meinschaft Internistische Onkologie. Ann Oncol 2008; 19:1882-7.
18. Shankaran V, Mulcahy MF, Hochster HS. Docetaxel, oxali-platin, and 5-fluorouracil for the treatment of metastatic or unresectable gastric or gastroesophageal junction (GEJ) adenocarcinomas: Preliminary results of a phase II study. 2009 Gastrointestinal Cancers Symposium 2009:Abstract No 47.
19. Du C, Wang J, Huang J, Zhang D. Docetaxel plus FOLFOX4 as first-line therapy for advanced esophagogastric junction or gastric adenocarcinoma: A report of phase II study in a single center in China. 2010 Gastrointestinal Cancers Symposium 2010:Abstract No: 94.
20. Anderson EJ, Miner T, Mcnulty B. A phase II Brown University Oncology Group study of docetaxel, oxaliplatin, and capecitabine (DOC) for metastatic esophagogastric cancer. J Clin Oncol 2009;27(Suppl):abstr e15541.
21. Van Cutsem E, Boni C, Tabernero J, Massuti B. Randomized phase II study (GATE study) of docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer. J Clin Oncol 2011; 29(Suppl):abstr 4018.
22. Andersen M, Schonnemann KR, Yilmaz M, Jensen HA, Vestermark LW, Pfeiffer P. Phase I study of docetaxel, oxali-platin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer. Acta Oncol 2010;49:1246-52.
23. Liu Y, Ma T, Ye ZB, Zhang J, Zhu ZG. Efficacy and safety evaluation of docetaxel plus oxaliplatin and capecitabine in the treatment of advanced gastric adenocarcinoma: A single center non-controlled phase II clinical trial. Zhonghua Wei Chang Wai Ke Za Zhi 2010;13:177-80.
24. Amarantidis K, Xenidis N, Chelis L, Chamalidou E, Dimopoulos P, Michailidis P, et al. Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer. Oncology 2011;80:359-65.
25. Thuss-Patience PC, Hofheinz RD, Arnold D, Florschutz A, Daum S, Kretzschmar A, et al. Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: A phase II study of the Arbe-itsgemeinschaft Internistische Onkologie (AIO). Ann Oncol 2012;23:2827-34.